Retina Consultants San Diego

Running trials

• Recruiting

  A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

  NCT07215390· Phase 2· Source

• Recruiting

  Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

  NCT06662162· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

  NCT06668064· Phase 3· Source

• Recruiting

  A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Phase 2/3· Source

• Active, not recruiting

  Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

  NCT06087458· Phase 1/2· Source

• Active, not recruiting

  An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  NCT05300724· Source

• Active, not recruiting

  Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

  NCT05296447· Phase 2· Source

• Enrolling by invitation

  Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

  NCT05210803· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration5 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

  NCT05891548· Phase 2· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Source

• Completed

  Safety and Efficacy of AM712 in Patients with NAMD

  NCT05345769· Phase 1· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

  NCT05151731· Phase 2· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Source

• Terminated

  EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04437368· Phase 2· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source